Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 6, 2025 | ReEngage Therapeutics Completes First Tranche of Bridge Round | Funding allows company to prepare for Phase 1b clinical trial This will allow us to accelerate the development of MTB-9655 in its first indication, chemotherapy-resistant metastatic colorectal cancer.” — Thomas Kim, CEOHOUSTON, TX, UNITED S... |
| May 7, 2025 | ReEngage Therapeutics Invited to Present at Multiple Investor Events | ReEngage building opportunities to speak with investors as it launches seed round HOUSTON, TX, UNITED STATES, May 7, 2025 /EINPresswire.com/ -- ReEngage Therapeutics, a biotech company pioneering epigenetics to treat longevity-related disea... |
| Feb 11, 2025 | ReEngage Therapeutics Joins Texas Medical Center’s 2025 Accelerator for Cancer Therapeutics | ReEngage is one of twenty-four entities chosen through a selective process to be immersed in the nine-month program funded by CPRIT HOUSTON, TX, UNITED STATES, February 11, 2025 /EINPresswire.com/ -- ReEngage Therapeutics, a biotech company... |
| Jul 9, 2024 | ReEngage Therapeutics Announces Research Agreement to Accelerate Development of ACSS2 Inhibitors as Cancer Therapies | ReEngage partners with globally-recognized cancer center to study ACSS2 and its role in acetate metabolism, histone modification and DNA Damage Response HOUSTON, TX, USA, July 9, 2024 /EINPresswire.com/ -- ReEngage Therapeutics, a biotech c... |
| May 21, 2024 | ReEngage Therapeutics Launches to Develop ACSS2 Inhibitor Compounds for Cancer Indications | Expands therapeutic reach of novel class with potential in established oncology data HOUSTON, TEXAS, UNITED STATES, May 21, 2024 /EINPresswire.com/ -- ReEngage Therapeutics, a biotech company pioneering epigenetics to treat longevity-relate... |
| ReEngage Therapeutics | “ReEngage” |
Reviews 0
FAQ about ReEngage
What has the press written about ReEngage?
Parsers VC has collected 7 articles mentioning ReEngage, among them “ReEngage Therapeutics Completes First Tranche of Bridge Round” (Aug 6, 2025) and “ReEngage Therapeutics Invited to Present at Multiple Investor Events” (May 7, 2025).
Is ReEngage still active?
Yes, ReEngage is active; its latest activity on Parsers VC dates from May 18, 2026.